BRPI0513692A - marcadores de urina para detecção de cáncer de bexiga - Google Patents

marcadores de urina para detecção de cáncer de bexiga

Info

Publication number
BRPI0513692A
BRPI0513692A BRPI0513692-0A BRPI0513692A BRPI0513692A BR PI0513692 A BRPI0513692 A BR PI0513692A BR PI0513692 A BRPI0513692 A BR PI0513692A BR PI0513692 A BRPI0513692 A BR PI0513692A
Authority
BR
Brazil
Prior art keywords
bladder cancer
detection
processes
urine
tumors
Prior art date
Application number
BRPI0513692-0A
Other languages
English (en)
Inventor
Parry John Guilford
Natalie Jane Kerr
Robert Pollock
Original Assignee
Pacific Edge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Edge Biotechnology Ltd filed Critical Pacific Edge Biotechnology Ltd
Priority to BR122020001099-1A priority Critical patent/BR122020001099B1/pt
Publication of BRPI0513692A publication Critical patent/BRPI0513692A/pt
Publication of BRPI0513692B1 publication Critical patent/BRPI0513692B1/pt
Publication of BRPI0513692B8 publication Critical patent/BRPI0513692B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MARCADORES DE URINA PARA DETECçãO DE CáNCER DE BEXIGA. A detecção precoce de tumores é um determinante principal da sobrevivência de pacientes sofrendo de tumores, incluindo tumores de bexiga. Os membros da família BTM ou UBTM podem ser altamente e coerentemente acumulados no tecido tumoral de bexiga e outros tecidos tumorais e/ou ser acumulados na urina de paciente e assim são marcadores para câncer de bexiga e de outros tipos. Em certas modalidades, BTMs ou UBTMs podem se acumular na urina e a detecção dos membros da família UBTM pode ser uma abordagem para diagnóstico eficiente. Em algumas modalidades, os processos de PCR quantitativa possuem vantagens sobre os processos de microarranjo. Em outras modalidades, a detecção e a quantificação de um grande número de BTMs ou de UBTMs podem aumentar a sensibilidade e a especificidade da detecção do câncer de bexiga e, portanto, fornecem processos para a determinação do estágio e do tipo de câncer de bexiga. Os kits fornecem maneiras convenientes fáceis para a realização dos processos desta invenção.
BRPI0513692A 2004-07-23 2005-07-22 processos para detecção de câncer de bexiga em um indivíduo BRPI0513692B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020001099-1A BR122020001099B1 (pt) 2004-07-23 2005-07-22 Processos para a detecção de câncer de bexiga em indivíduos

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ53428904 2004-07-23
NZ534,289 2004-07-23
NZ539,219 2005-04-04
NZ53921905 2005-04-04
US69261905P 2005-06-20 2005-06-20
US60/692,619 2005-06-20
PCT/US2005/026055 WO2006012522A1 (en) 2004-07-23 2005-07-22 Urine markers for detection of bladder cancer

Publications (3)

Publication Number Publication Date
BRPI0513692A true BRPI0513692A (pt) 2008-05-13
BRPI0513692B1 BRPI0513692B1 (pt) 2020-11-10
BRPI0513692B8 BRPI0513692B8 (pt) 2021-07-27

Family

ID=45755636

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020001099-1A BR122020001099B1 (pt) 2004-07-23 2005-07-22 Processos para a detecção de câncer de bexiga em indivíduos
BRPI0513692A BRPI0513692B8 (pt) 2004-07-23 2005-07-22 processos para detecção de câncer de bexiga em um indivíduo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020001099-1A BR122020001099B1 (pt) 2004-07-23 2005-07-22 Processos para a detecção de câncer de bexiga em indivíduos

Country Status (14)

Country Link
US (1) US11130789B2 (pt)
EP (5) EP2444505B1 (pt)
JP (6) JP5179177B2 (pt)
KR (11) KR20070051286A (pt)
CN (3) CN101027412B (pt)
AU (1) AU2005266948A1 (pt)
BR (2) BR122020001099B1 (pt)
CA (5) CA2862993C (pt)
DK (2) DK2444505T3 (pt)
ES (4) ES2540108T3 (pt)
NZ (2) NZ595684A (pt)
PT (2) PT2434024T (pt)
TW (4) TWI661199B (pt)
WO (1) WO2006012522A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2444505T3 (da) 2004-07-23 2017-01-02 Pacific Edge Ltd Urinmarkører til påvisning af blærecancer
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
ES2344932B1 (es) * 2009-02-10 2011-06-30 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe Metodo para la deteccion de cancer de vejiga.
US9315802B2 (en) 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
US20130203059A1 (en) * 2010-07-02 2013-08-08 Topogen, Inc. Method for Diagnosis of Bladder Cancer and Related Kits
EP2630261B1 (en) 2010-10-19 2019-04-17 Oslo Universitetssykehus HF Methods and biomarkers for detection of bladder cancer
NZ589251A (en) * 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
US9663781B2 (en) 2010-12-30 2017-05-30 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
WO2013134693A1 (en) * 2012-03-09 2013-09-12 Insight Genetics, Inc. Methods and compositions relating to diagnosing and treating receptor tyrosine kinase related cancers
WO2014087191A1 (en) 2012-12-04 2014-06-12 Scinopharm Taiwan Ltd. Method for selecting a pool of molecules
CN103033625B (zh) * 2012-12-19 2014-12-24 中国科学院生物物理研究所 一种人膀胱癌细胞化学发光检测试剂盒及其制备方法
AU2014224523A1 (en) * 2013-03-08 2015-09-24 Noviogendix Research B.V. Molecular markers in bladder cancer
EP3339450A3 (en) * 2013-03-08 2018-08-08 MDxHealth Research B.V. Molecular markers in bladder cancer
WO2014182330A1 (en) 2013-05-06 2014-11-13 Hitachi Chemical Company Ltd Devices and methods for capturing target molecules
DK3071973T3 (da) * 2013-11-21 2021-01-11 Pacific Edge Ltd Triage af patienter med asymptomatisk hæmaturi ved hjælp af genotype- og fænotypebiomarkører
CN105891500A (zh) * 2015-01-16 2016-08-24 刘晓强 一种快速检测膀胱癌的试纸
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
JP6769596B2 (ja) * 2016-05-30 2020-10-14 学校法人北里研究所 膀胱癌診断薬及び生体試料の判定方法
RU2670655C2 (ru) * 2017-02-20 2018-10-24 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения Российской Федерации" Способ определения риска рецидива поверхностного рака мочевого пузыря после оперативного лечения
CN108866194B (zh) * 2018-08-16 2021-03-26 杭州可帮基因科技有限公司 一组用于膀胱癌检测的基因及其应用
CN109055559A (zh) * 2018-09-28 2018-12-21 爱尔生基因医学科技有限公司 一种检测膀胱癌的特异性引物和试剂盒及其检测方法
WO2020071489A1 (ja) * 2018-10-04 2020-04-09 国立大学法人大阪大学 尿路上皮がんを検査する方法
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109884301B (zh) * 2019-02-26 2023-03-31 上海市第十人民医院 一种用于肌层浸润性膀胱癌生存预后预测的生物标记物及其应用
JP2022553825A (ja) * 2019-10-31 2022-12-26 ショウワ デンコウ マテリアルズ（アメリカ），インコーポレイテッド 尿路上皮がん用の尿中ｅｖ ｒｎａバイオマーカー
JP2023530137A (ja) 2020-06-19 2023-07-13 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ 局所抗菌組成物
RU2756255C1 (ru) * 2020-11-06 2021-09-28 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого" Министерства Здравоохранения Российской Федерации Способ раннего выявления рака мочевого пузыря с помощью цитофлоуриметрического анализа клеточного осадка мочи
CN114686607B (zh) * 2020-12-31 2023-09-26 深圳华大生命科学研究院 棒状杆菌作为尿液微生物标志物在制备用于检测膀胱癌的相关检测产品中的应用
KR102632423B1 (ko) * 2021-02-26 2024-01-31 충북대학교 산학협력단 비근침윤성 방광암의 예후 예측을 위한 바이오마커 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
AUPN245295A0 (en) * 1995-04-13 1995-05-11 Johnson & Johnson Research Pty. Limited Assay for genetic abnormalities
CA2266325C (en) 1996-09-24 2012-07-17 Lxr Biotechnology, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6495532B1 (en) 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
DK0920539T3 (da) 1997-05-30 2006-07-24 Xenomics Fremgangsmåder til detektion af nukleinsyresekvenser i urin
US6492144B1 (en) 1997-05-30 2002-12-10 Diagen Corporation Methods for detection of nucleic acid sequences in urine
AU4158799A (en) * 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
ATE393220T1 (de) * 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
AU1492601A (en) 1999-09-27 2001-04-30 Quark Biotech, Inc. Sequences characteristic of bladder cancer
US6419896B1 (en) 2000-03-03 2002-07-16 Bert Vogelstein Non-invasive approach for assessing tumors in living animals
IT1318504B1 (it) * 2000-05-08 2003-08-27 Talent Srl Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina.
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
CA2320549A1 (en) 2000-09-25 2002-03-25 Eastern Virginia Medical College Biomarkers of transitional cell carcinoma of the bladder
WO2002086084A2 (en) 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
EP1285970A3 (en) 2001-06-26 2004-05-19 National Taiwan University Metastasis-associated genes
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030113758A1 (en) * 2001-08-14 2003-06-19 Pierre Oudet Method for the in vitro diagnosis of a predisposition to bladder cancer or of the occurrence of bladder cancer and a kit for performing said diagnostic method
US20040043436A1 (en) * 2001-09-21 2004-03-04 Antonia Vlahou Biomarkers of transitional cell carcinoma of the bladder
JP2003279578A (ja) * 2002-03-26 2003-10-02 National Shikoku Cancer Center 癌の診断支援方法及びそのキット
US20050032065A1 (en) 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
WO2004018676A2 (en) * 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
US7217515B2 (en) * 2002-09-30 2007-05-15 Chi Mei Foundation Medical Center HURP gene as a molecular marker for bladder cancer
EP1550690A4 (en) 2002-10-08 2006-12-06 Denki Kagaku Kogyo Kk HEAT SHRINKABLE FOIL
EP1563098A2 (en) * 2002-11-01 2005-08-17 Aros Applied Biotechnology Aps Gene expression in biological conditions
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
DK2444505T3 (da) 2004-07-23 2017-01-02 Pacific Edge Ltd Urinmarkører til påvisning af blærecancer
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer

Also Published As

Publication number Publication date
EP2434024A1 (en) 2012-03-28
DK2434024T3 (da) 2017-01-02
KR20140122285A (ko) 2014-10-17
AU2005266948A1 (en) 2006-02-02
CA2862993C (en) 2019-01-15
KR20180023048A (ko) 2018-03-06
KR20220012933A (ko) 2022-02-04
CN107326066B (zh) 2021-10-26
TW201734454A (zh) 2017-10-01
BRPI0513692B1 (pt) 2020-11-10
JP6309594B2 (ja) 2018-04-11
NZ553297A (en) 2010-10-29
EP2444505B1 (en) 2016-09-07
KR20070051286A (ko) 2007-05-17
CA3147177A1 (en) 2006-02-02
JP6174303B2 (ja) 2017-08-02
KR20220012993A (ko) 2022-02-04
CN101027412B (zh) 2017-04-26
CN107326066A (zh) 2017-11-07
EP1784503A4 (en) 2009-08-12
EP2434023A1 (en) 2012-03-28
BR122020001099B1 (pt) 2021-12-14
JP2017060489A (ja) 2017-03-30
EP2434023B1 (en) 2015-02-25
NZ595684A (en) 2013-06-28
CN101027412A (zh) 2007-08-29
EP2434024B1 (en) 2016-09-07
CA2616277A1 (en) 2006-02-02
KR20130027059A (ko) 2013-03-14
WO2006012522A1 (en) 2006-02-02
ES2540108T3 (es) 2015-07-08
KR20160105914A (ko) 2016-09-07
CA2616277C (en) 2023-03-07
KR20220116354A (ko) 2022-08-22
TW201217787A (en) 2012-05-01
TWI585411B (zh) 2017-06-01
CA2862993A1 (en) 2006-02-02
KR20120059648A (ko) 2012-06-08
CN114250299A (zh) 2022-03-29
KR20130137054A (ko) 2013-12-13
TWI661199B (zh) 2019-06-01
JP2012185173A (ja) 2012-09-27
JP6248297B2 (ja) 2017-12-20
JP2015156866A (ja) 2015-09-03
ES2612482T3 (es) 2017-05-17
TW201525463A (zh) 2015-07-01
US20100273148A1 (en) 2010-10-28
JP2008507558A (ja) 2008-03-13
EP2444505A2 (en) 2012-04-25
DK2444505T3 (da) 2017-01-02
ES2612197T3 (es) 2017-05-12
ES2538504T3 (es) 2015-06-22
US11130789B2 (en) 2021-09-28
PT2434024T (pt) 2017-01-13
EP2444505A3 (en) 2012-07-18
CA3147162A1 (en) 2006-02-02
JP6670774B2 (ja) 2020-03-25
EP2436779A1 (en) 2012-04-04
PT2444505T (pt) 2017-01-13
JP2018183162A (ja) 2018-11-22
KR20220012881A (ko) 2022-02-04
CA3147181A1 (en) 2006-02-02
TWI503416B (zh) 2015-10-11
TWI540321B (zh) 2016-07-01
JP2017104118A (ja) 2017-06-15
KR101514582B1 (ko) 2015-05-04
BRPI0513692B8 (pt) 2021-07-27
JP5179177B2 (ja) 2013-04-10
KR101652854B1 (ko) 2016-08-31
EP2436779B1 (en) 2015-03-25
EP1784503A1 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
BRPI0513692A (pt) marcadores de urina para detecção de cáncer de bexiga
Taniguchi et al. Transcriptional silencing of hedgehog‐interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer
EP2301626A3 (en) Antibiotic for use in local infection
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
EA201400710A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
EP1350085A4 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
Tang et al. First evidence that sika deer (Cervus nippon) velvet antler extract suppresses migration of human prostate cancer cells
EP1698898A3 (en) Prognostic, diagnostic and therapeutic significance in detecting and using TIN-antigen (Tubulo-Interstitial nephritis antigen) and its segments
Wiener-Carrillo et al. Intussusception secondary to a carcinoid tumor in an adult patient
Perakakis et al. Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype
Mikkelsen et al. Mucosal melanoma
WO2005065328A3 (en) Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
Shah et al. 217; YAP Is Ready to Rac and Rho: Elucidation of a Novel YAP-Driven Network That Potentiates Brain Cancer Cell Dispersal and Confers Poor Survival in Patients
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
Kouhen et al. Primary urachal adenocarcinoma treated effectively with surgery and post operative chemoradiation therapy: Case Report with review of the literature
ATE498020T1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
Dilley et al. Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients.
Lococo et al. Pulmonary metastases from parachordoma
Yimer et al. Detection of Cancer Signal for over 50 AJCC Cancer Types with a Multi‑Cancer Early Detection Test
Langan et al. Melanoma of the oral cavity
Prakash et al. Colon cancer: general diagnostic and treatment
Karima STROMAL TUMOR IN VON-RECKLINGHAUSEN DISEASE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), C12Q 1/6886 (2018.01), G01N

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2784 DE 14-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.